Summit Therapeutics Inc. (BMV:SMMT)
| Market Cap | 151.64B -35.3% |
| Revenue (ttm) | n/a |
| Net Income | -15.01B |
| EPS | -20.46 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 290.00 |
| Previous Close | 292.00 |
| Day's Range | 290.00 - 290.00 |
| 52-Week Range | 281.00 - 430.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Feb 23, 2027 |
About Summit Therapeutics
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth facto... [Read more]
News
Summit Therapeutics to Host Corporate Update and Operational Progress Call on November 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) will host a corporate update and operational progress conference call and webcast on Monday, November 30, 2026. The call is sc...
Summit Therapeutics price target lowered to $11 from $13 at Leerink
Leerink lowered the firm’s price target on Summit Therapeutics (SMMT) to $11 from $13 and keeps a Market Perform rating on the shares. The firm says that removing ivonescimab revenues…
Bernstein downgrades Summit Therapeutics to Underperform, lowers target to $8.30
As previously reported, Bernstein analyst Jeffrey Walch downgraded Summit Therapeutics (SMMT) to Underperform from Market Perform with a price target of $8.30, down from $11.90. The firm has now uncer...
Summit Therapeutics downgraded to Underperform from Market Perform at Bernstein
Bernstein analyst Jeffrey Walch downgraded Summit Therapeutics (SMMT) to Underperform from Market Perform with a price target of $8.30, down from $11.90.
Summit Therapeutics initiates new global Phase 3 trial of ivonescimab
Summit Therapeutics (SMMT) announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF bispecific antibody, in non-small cell lung cancer. T...
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study in Unresectable Stage III Non-Small Cell Lung Cancer
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation of a new global Phase III clinical trial of ivonescimab, an investigational, novel PD-1 x VEGF ...
Summit Therapeutics' stock tumbles again as FDA recommends new trial for lung-cancer drug
Summit Therapeutics' stock tumbled again Tuesday after the Food and Drug Administration said the biotech company should run a new clinical trial for its experimental lung-cancer drug.
Summit Therapeutics falls -14.4%
Summit Therapeutics (SMMT) is down -14.4%, or -$2.04 to $12.11.
Summit's FDA Setback Is a Reality Check for Next-Gen Cancer Drugs
Summit Therapeutics stock sinks as regulators decline to approve ivonescimab, a next-generation cancer therapy backed by AstraZeneca.
The FDA declined to approve one of biotech's most closely watched cancer drugs
The regulator told Summit Therapeutics that the lung-cancer drug needs to prove it can help people live longer.
Why Is Summit Therapeutics Stock (SMMT) Plunging in Premarket Today, November 16?
Summit Therapeutics ($SMMT) stock fell in Monday’s premarket trading after the U.S. Food and Drug Administration (FDA) rejected its lung cancer drug, ivonescimab, for patients whose cancer worsened af...
Summit Therapeutics price target lowered to $18 from $20 at Barclays
Barclays analyst Etzer Darout lowered the firm’s price target on Summit Therapeutics (SMMT) to $18 from $20 and keeps an Equal Weight rating on the shares. The firm says the…
Summit Therapeutics price target lowered to $42 from $43 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on Summit Therapeutics (SMMT) to $42 from $43 and keeps a Buy rating on the shares. The firm cites the complete…
Summit announces US FDA issued CRL regarding BLA for ivonescimab
Summit Therapeutics (SMMT) announced that the U.S. Food and Drug Administration, FDA, has issued a Complete Response Letter, CRL, regarding the Biologics License Application, BLA, for ivonescimab in c...
Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics Lic...
Summit Therapeutics price target lowered to $37 from $38 at Stifel
Stifel lowered the firm’s price target on Summit Therapeutics (SMMT) to $37 from $38 and keeps a Buy rating on the shares.
Summit Therapeutics reports Q3 EPS (20c), consensus (21c)
“This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with As...
Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on...
Summit Therapeutics Earnings release: Q3 2026
Summit Therapeutics released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Summit Therapeutics Quarterly report: Q3 2026
Summit Therapeutics has published its Q3 2026 quarterly earnings report on November 4, 2026.
Summit Therapeutics Transcript: EGM 2026
Shareholders approved a charter amendment increasing authorized common shares from 1 billion to 2 billion. Final results were to be reported on Form 8-K within four business days.
Summit, Lunit announce research agreement to evaluate Lunit SCOPE IO
Lunit and Summit Therapeutics (SMMT) announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summ...
Summit’s partner announces results from Phase III HARMONi-GI1 study
Summit Therapeutics (SMMT) noted that its partner Akeso announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibo...
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, ...
Lunit and Summit Therapeutics Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Research Will Use Lunit's AI-powered Pathology Platform to Analyze H&E Whole-Slide Images and Generate Scalable Insights into Tumor Microenvironment Biology SEOUL, South Korea, Oct. 24, 2026 /PRNewswi...